{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:41:37Z","timestamp":1792597297803,"version":"4.5.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s11060-025-05082-1","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T11:07:39Z","timestamp":1747739259000},"page":"329-340","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The hormonal nexus in PIK3CA-mutated meningiomas: implications for targeted therapy and clinical trial design"],"prefix":"10.1007","volume":"174","author":[{"given":"Matthew","family":"Abikenari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Regev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vratko","family":"Himic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeeva","family":"Jeyaretna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Fountain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"5082_CR1","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/neuonc\/noab200","volume":"23","author":"QT Ostrom","year":"2021","unstructured":"Ostrom QT, Cioffi G, Waite K et al (2021) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united States in 2014\u20132018. Neuro-Oncol 23:iii1\u2013iii105","journal-title":"Neuro-Oncol"},{"key":"5082_CR2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11060-010-0386-3","volume":"99","author":"J Wiemels","year":"2010","unstructured":"Wiemels J, Wrensch M, Claus EB (2010) Epidemiology and etiology of meningioma. J Neurooncol 99:307\u2013314","journal-title":"J Neurooncol"},{"key":"5082_CR3","doi-asserted-by":"publisher","unstructured":"Weill A, Nguyen P, Labidi M et al Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study. Epub ahead of print 3 February 2021. https:\/\/doi.org\/10.1136\/bmj.n37","DOI":"10.1136\/bmj.n37"},{"key":"5082_CR4","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1016\/j.wneu.2020.04.168","volume":"140","author":"S Portet","year":"2020","unstructured":"Portet S, Banor T, Bousquet J et al (2020) New insights into expression of hormonal receptors by meningiomas. World Neurosurg 140:e87\u2013e96","journal-title":"World Neurosurg"},{"key":"5082_CR5","doi-asserted-by":"publisher","first-page":"104154","DOI":"10.1016\/j.bas.2024.104154","volume":"5","author":"G Reuter","year":"2025","unstructured":"Reuter G, Potorac I, de Herdt C et al (2025) Recommendations on the management of meningioma and sex hormone therapy: the results of a collaborative effort between neurosurgical, endocrine and gynecological societies. Brain Spine 5:104154","journal-title":"Brain Spine"},{"key":"5082_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/B978-0-12-804280-9.00006-8","volume":"169","author":"MW Youngblood","year":"2020","unstructured":"Youngblood MW, G\u00fcnel M (2020) Molecular genetics of meningiomas. Handb Clin Neurol 169:101\u2013119","journal-title":"Handb Clin Neurol"},{"key":"5082_CR7","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/neuonc\/nov316","volume":"18","author":"M Abedalthagafi","year":"2016","unstructured":"Abedalthagafi M, Bi WL, Aizer AA et al (2016) Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro-Oncol 18:649\u2013655","journal-title":"Neuro-Oncol"},{"key":"5082_CR8","unstructured":"Sahm F, Bertero L, Brandner S et al (2024) EANO guideline on molecular testing of meningiomas for targeted therapy selection. Neuro-Oncol; noae253"},{"key":"5082_CR9","doi-asserted-by":"publisher","first-page":"5075","DOI":"10.36922\/mi.5075","volume":"0","author":"MA Abikenari","year":"2024","unstructured":"Abikenari MA, Enayati I, Fountain DM et al (2024) Navigating glioblastoma therapy: A narrative review of emerging immunotherapeutics and small-molecule inhibitors. Microbes Immun 0:5075","journal-title":"Microbes Immun"},{"key":"5082_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/glioma.glioma_4_24","volume":"7","author":"M Abikenari","year":"2024","unstructured":"Abikenari M, Schonfeld E, Choi J et al (2024) Revisiting glioblastoma classification through an immunological lens: A narrative review. Glioma 7:3\u20139","journal-title":"Glioma"},{"key":"5082_CR11","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s00401-005-0021-0","volume":"111","author":"JC Pang","year":"2006","unstructured":"Pang JC, Chung NYF, Chan NHL et al (2006) Rare mutation of PIK3CA in meningiomas. Acta Neuropathol (Berl) 111:284\u2013285","journal-title":"Acta Neuropathol (Berl)"},{"key":"5082_CR12","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.3892\/ol.2014.2042","volume":"7","author":"M Bujko","year":"2014","unstructured":"Bujko M, Kober P, Tysarowski A et al (2014) EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas. Oncol Lett 7:2019\u20132022","journal-title":"Oncol Lett"},{"key":"5082_CR13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s40478-020-01040-2","volume":"8","author":"EA Williams","year":"2020","unstructured":"Williams EA, Santagata S, Wakimoto H et al (2020) Distinct genomic subclasses of high-grade\/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic. Acta Neuropathol Commun 8:171","journal-title":"Acta Neuropathol Commun"},{"key":"5082_CR14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1093\/neuonc\/now029","volume":"18","author":"G Zadeh","year":"2016","unstructured":"Zadeh G, Karimi S, Aldape KD (2016) PIK3CA mutations in meningioma. Neuro-Oncol 18:603\u2013604","journal-title":"Neuro-Oncol"},{"key":"5082_CR15","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/ng.3651","volume":"48","author":"VE Clark","year":"2016","unstructured":"Clark VE, Harmanc\u0131 AS, Bai H et al (2016) Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat Genet 48:1253\u20131259","journal-title":"Nat Genet"},{"key":"5082_CR16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3171\/2023.11.JNS231936","volume":"141","author":"L Hua","year":"2024","unstructured":"Hua L, Alkhatib M, Fujio S et al (2024) Genetic characterization and mutational profiling of foramen magnum meningiomas: a multi-institutional study. J Neurosurg 141:72\u201378","journal-title":"J Neurosurg"},{"key":"5082_CR17","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.18632\/oncotarget.2209","volume":"5","author":"NM Davis","year":"2014","unstructured":"Davis NM, Sokolosky M, Stadelman K et al (2014) Deregulation of the EGFR\/PI3K\/PTEN\/Akt\/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget 5:4603\u20134650","journal-title":"Oncotarget"},{"key":"5082_CR18","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.3390\/ijms22042061","volume":"22","author":"P Ko\u0142odziej","year":"2021","unstructured":"Ko\u0142odziej P, Nico\u015b M, Krawczyk PA et al (2021) The correlation of mutations and expressions of genes within the PI3K\/Akt\/mTOR pathway in breast Cancer\u2014A preliminary study. Int J Mol Sci 22:2061","journal-title":"Int J Mol Sci"},{"key":"5082_CR19","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1001\/jamaoncol.2016.5281","volume":"3","author":"RK Basho","year":"2017","unstructured":"Basho RK, Gilcrease M, Murthy RK et al (2017) Targeting the PI3K\/AKT\/mTOR pathway for the treatment of mesenchymal Triple-Negative breast cancer: evidence from a phase 1 trial of mTOR Inhibition in combination with liposomal doxorubicin and bevacizumab. JAMA Oncol 3:509\u2013515","journal-title":"JAMA Oncol"},{"key":"5082_CR20","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/neuros\/nyab175","volume":"89","author":"EHJ Voormolen","year":"2021","unstructured":"Voormolen EHJ, Champagne PO, Roca E et al (2021) Intracranial meningiomas decrease in volume on magnetic resonance imaging after discontinuing progestin. Neurosurgery 89:308\u2013314","journal-title":"Neurosurgery"},{"key":"5082_CR21","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1111\/ene.15423","volume":"29","author":"L Hoisnard","year":"2022","unstructured":"Hoisnard L, Laanani M, Passeri T et al (2022) Risk of intracranial meningioma with three potent progestogens: A population-based case-control study. Eur J Neurol 29:2801\u20132809","journal-title":"Eur J Neurol"},{"key":"5082_CR22","doi-asserted-by":"publisher","first-page":"e078078","DOI":"10.1136\/bmj-2023-078078","volume":"384","author":"N Roland","year":"2024","unstructured":"Roland N, Neumann A, Hoisnard L et al (2024) Use of progestogens and the risk of intracranial meningioma: National case-control study. BMJ 384:e078078","journal-title":"BMJ"},{"key":"5082_CR23","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1016\/j.wneu.2020.11.175","volume":"147","author":"X Yang","year":"2021","unstructured":"Yang X, Liu F, Zheng J et al (2021) Relationship between oral contraceptives and the risk of gliomas and meningiomas: A Dose-Response Meta-Analysis and systematic review. World Neurosurg 147:e148\u2013e162","journal-title":"World Neurosurg"},{"key":"5082_CR24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1093\/aje\/kwj254","volume":"164","author":"A Wigertz","year":"2006","unstructured":"Wigertz A, L\u00f6nn S, Mathiesen T et al (2006) Risk of brain tumors associated with exposure to exogenous female sex hormones. Am J Epidemiol 164:629\u2013636","journal-title":"Am J Epidemiol"},{"key":"5082_CR25","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1111\/ajco.13138","volume":"15","author":"X Shu","year":"2019","unstructured":"Shu X, Jiang Y, Wen T et al (2019) Association of hormone replacement therapy with increased risk of meningioma in women: A hospital-based multicenter study with propensity score matching. Asia Pac J Clin Oncol 15:e147\u2013e153","journal-title":"Asia Pac J Clin Oncol"},{"key":"5082_CR26","first-page":"197","volume":"13","author":"I Kanaan","year":"2003","unstructured":"Kanaan I, Jallu A, Kanaan H (2003) Management strategy for meningioma in pregnancy: A clinical study. Skull Base Off J North Am Skull Base Soc Al 13:197\u2013203","journal-title":"Skull Base Off J North Am Skull Base Soc Al"},{"key":"5082_CR27","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/00006123-199602000-00027","volume":"38","author":"RS Carroll","year":"1996","unstructured":"Carroll RS, Schrell UM, Zhang J et al (1996) Dopamine D1, dopamine D2, and prolactin receptor messenger ribonucleic acid expression by the polymerase chain reaction in human meningiomas. Neurosurgery 38:367\u2013375","journal-title":"Neurosurgery"},{"key":"5082_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/BF01057032","volume":"16","author":"E Jimenez-Hakim","year":"1993","unstructured":"Jimenez-Hakim E, el-Azouzi M, Black PM (1993) The effect of prolactin and Bombesin on the growth of meningioma-derived cells in monolayer culture. J Neurooncol 16:185\u2013190","journal-title":"J Neurooncol"},{"key":"5082_CR29","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1227\/NEU.0b013e31826adf65","volume":"71","author":"EA Lusis","year":"2012","unstructured":"Lusis EA, Scheithauer BW, Yachnis AT et al (2012) Meningiomas in pregnancy: a clinicopathologic study of 17 cases. Neurosurgery 71:951\u2013961","journal-title":"Neurosurgery"},{"key":"5082_CR30","first-page":"86","volume":"13","author":"A Gurcay","year":"2022","unstructured":"Gurcay A, Bozkurt I, Senturk S et al (2022) Diagnosis, treatment, and management strategy of meningioma during pregnancy. Asian J Neurosurg 13:86\u201389","journal-title":"Asian J Neurosurg"},{"key":"5082_CR31","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/annonc\/mdx763","volume":"29","author":"M Peyre","year":"2018","unstructured":"Peyre M, Gaillard S, de Marcellus C et al (2018) Progestin-associated shift of meningioma mutational landscape. Ann Oncol 29:681\u2013686","journal-title":"Ann Oncol"},{"key":"5082_CR32","doi-asserted-by":"publisher","first-page":"luae173","DOI":"10.1210\/jcemcr\/luae173","volume":"2","author":"MI Balcerek","year":"2024","unstructured":"Balcerek MI, Hovelroud R, Ruhl M et al (2024) Giant intracranial meningiomas requiring surgery in 2 transgender women treated with cyproterone acetate. JCEM Case Rep 2:luae173","journal-title":"JCEM Case Rep"},{"key":"5082_CR33","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00701-021-05005-9","volume":"164","author":"T Passeri","year":"2022","unstructured":"Passeri T, Giammattei L, Le Van T et al (2022) Atypical evolution of meningiomatosis after discontinuation of cyproterone acetate: clinical cases and histomolecular characterization. Acta Neurochir (Wien) 164:255\u2013263","journal-title":"Acta Neurochir (Wien)"},{"key":"5082_CR34","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41417-023-00621-2","volume":"30","author":"P-C C\u00f4mes","year":"2023","unstructured":"C\u00f4mes P-C, Le Van T, Tran S et al (2023) Respective roles of Pik3ca mutations and cyproterone acetate impregnation in mouse meningioma tumorigenesis. Cancer Gene Ther 30:1114\u20131123","journal-title":"Cancer Gene Ther"},{"key":"5082_CR35","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.31557\/APJCP.2022.23.3.1047","volume":"23","author":"RG Malueka","year":"2022","unstructured":"Malueka RG, Hartanto RA, Setyawan NH et al (2022) Association of hormonal contraception with meningioma location in Indonesian patients. Asian Pac J Cancer Prev APJCP 23:1047\u20131051","journal-title":"Asian Pac J Cancer Prev APJCP"},{"key":"5082_CR36","doi-asserted-by":"publisher","first-page":"vdz003","DOI":"10.1093\/noajnl\/vdz003","volume":"1","author":"S Portet","year":"2019","unstructured":"Portet S, Naoufal R, Tachon G et al (2019) Histomolecular characterization of intracranial meningiomas developed in patients exposed to high-dose cyproterone acetate: an antiandrogen treatment. Neuro-Oncol Adv 1:vdz003","journal-title":"Neuro-Oncol Adv"},{"key":"5082_CR37","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/annonc\/mdy010","volume":"29","author":"Z Du","year":"2018","unstructured":"Du Z, Santagata S (2018) Uncovering the links between systemic hormones and oncogenic signaling in the pathogenesis of meningioma. Ann Oncol Off J Eur Soc Med Oncol 29:537\u2013540","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"5082_CR38","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11060-022-04187-1","volume":"161","author":"DF Miyagishima","year":"2023","unstructured":"Miyagishima DF, Moliterno J, Claus E et al (2023) Hormone therapies in meningioma-where are we? J Neurooncol 161:297\u2013308","journal-title":"J Neurooncol"},{"key":"5082_CR39","doi-asserted-by":"publisher","first-page":"bqab259","DOI":"10.1210\/endocr\/bqab259","volume":"163","author":"M Hage","year":"2022","unstructured":"Hage M, Plesa O, Lemaire I et al (2022) Estrogen and progesterone therapy and meningiomas. Endocrinology 163:bqab259","journal-title":"Endocrinology"},{"key":"5082_CR40","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1007\/s10143-022-01817-0","volume":"45","author":"C Fodi","year":"2022","unstructured":"Fodi C, Skardelly M, Hempel J-M et al (2022) Correction to: the immunohistochemical expression of SSTR2A is an independent prognostic factor in meningioma. Neurosurg Rev 45:2993","journal-title":"Neurosurg Rev"},{"key":"5082_CR41","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00259-009-1115-z","volume":"36","author":"M Bartolomei","year":"2009","unstructured":"Bartolomei M, Bodei L, De Cicco C et al (2009) Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging 36:1407\u20131416","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5082_CR42","first-page":"507","volume":"62","author":"C Mirian","year":"2021","unstructured":"Mirian C, Duun-Henriksen AK, Maier A et al (2021) Somatostatin Receptor-Targeted radiopeptide therapy in Treatment-Refractory meningioma: individual patient data Meta-analysis. J Nucl Med Off Publ Soc Nucl Med 62:507\u2013513","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"5082_CR43","unstructured":"Antiestrogenic therapy of meningiomas\u2013a pilot study - PubMed, https:\/\/pubmed.ncbi.nlm.nih.gov\/4023903\/ (accessed 2 May 2025)."},{"key":"5082_CR44","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/BF01050266","volume":"15","author":"JW Goodwin","year":"1993","unstructured":"Goodwin JW, Crowley J, Eyre HJ et al (1993) A phase II evaluation of Tamoxifen in unresectable or refractory meningiomas: a Southwest oncology group study. J Neurooncol 15:75\u201377","journal-title":"J Neurooncol"},{"key":"5082_CR45","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1080\/07357900601062339","volume":"24","author":"SM Grunberg","year":"2006","unstructured":"Grunberg SM, Weiss MH, Russell CA et al (2006) Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest 24:727\u2013733","journal-title":"Cancer Invest"},{"key":"5082_CR46","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/BF00182088","volume":"8","author":"SM Grunberg","year":"1990","unstructured":"Grunberg SM, Weiss MH (1990) Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma. J Neurooncol 8:61\u201365","journal-title":"J Neurooncol"},{"key":"5082_CR47","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1007\/s00701-014-2188-4","volume":"156","author":"M Touat","year":"2014","unstructured":"Touat M, Lombardi G, Farina P et al (2014) Successful treatment of multiple intracranial meningiomas with the antiprogesterone receptor agent mifepristone (RU486). Acta Neurochir (Wien) 156:1831\u20131835","journal-title":"Acta Neurochir (Wien)"},{"key":"5082_CR48","doi-asserted-by":"publisher","first-page":"4093","DOI":"10.1200\/JCO.2015.61.6490","volume":"33","author":"Y Ji","year":"2015","unstructured":"Ji Y, Rankin C, Grunberg S et al (2015) Double-Blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol Off J Am Soc Clin Oncol 33:4093\u20134098","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"5082_CR49","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1212\/01.wnl.0000271382.62776.b7","volume":"69","author":"MC Chamberlain","year":"2007","unstructured":"Chamberlain MC, Glantz MJ, Fadul CE (2007) Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology 69:969\u2013973","journal-title":"Neurology"},{"key":"5082_CR50","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1212\/WNL.0000000000001153","volume":"84","author":"AD Norden","year":"2015","unstructured":"Norden AD, Ligon KL, Hammond SN et al (2015) Phase II study of monthly Pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology 84:280\u2013286","journal-title":"Neurology"},{"key":"5082_CR51","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3389\/fneur.2020.00373","volume":"11","author":"M Hrachova","year":"2020","unstructured":"Hrachova M, Nguyen ENT, Fu BD et al (2020) A retrospective interventional cohort study to assess the safety and efficacy of sandostatin LAR for treatment of recurrent and\/or refractory meningiomas. Front Neurol 11:373","journal-title":"Front Neurol"},{"key":"5082_CR52","first-page":"573","volume":"65","author":"C Eigler","year":"2024","unstructured":"Eigler C, McDougall L, Bauman A et al (2024) Radiolabeled somatostatin receptor antagonist versus agonist for peptide receptor radionuclide therapy in patients with therapy-Resistant meningioma: PROMENADE phase 0 study. J Nucl Med Off Publ Soc Nucl Med 65:573\u2013579","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"5082_CR53","unstructured":"Lutathera for the Treatment of Inoperable, Progressive Meningioma after External Beam Radiation Therapy - NCI (2016) https:\/\/www.cancer.gov\/about-cancer\/treatment\/clinical-trials\/search\/v?id=NCI-2019-05848 accessed 2 May 2025)."},{"key":"5082_CR54","unstructured":"Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors (2025) - National Brain Tumor Society. https:\/\/trials.braintumor.org\/trials\/NCT05278208 (accessed 2 May"},{"key":"5082_CR55","unstructured":"Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as imaging biomarker in patients with intracranial Meningioma - PubMed, https:\/\/pubmed.ncbi.nlm.nih.gov\/38048045\/ (accessed 2 May 2025)."},{"key":"5082_CR56","unstructured":"Alpelisib for PIK3CA-Mutated Hormone Receptor\u2013Positive advanced breast Cancer| new England journal of medicine, https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1813904 (accessed 2 May 2025)."},{"key":"5082_CR57","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1172\/JCI41680","volume":"120","author":"TW Miller","year":"2010","unstructured":"Miller TW, Hennessy BT, Gonz\u00e1lez-Angulo AM et al (2010) Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in Estrogen receptor-positive human breast cancer. J Clin Invest 120:2406\u20132413","journal-title":"J Clin Invest"},{"key":"5082_CR58","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s43018-021-00218-4","volume":"2","author":"P Castel","year":"2021","unstructured":"Castel P, Toska E, Engelman JA et al (2021) The present and future of PI3K inhibitors for cancer therapy. Nat Cancer 2:587\u2013597","journal-title":"Nat Cancer"},{"key":"5082_CR59","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/cancers9040034","volume":"9","author":"M Crumbaker","year":"2017","unstructured":"Crumbaker M, Khoja L, Joshua AM (2017) AR signaling and the PI3K pathway in prostate Cancer. Cancers 9:34","journal-title":"Cancers"},{"key":"5082_CR60","first-page":"342","volume":"12","author":"JJ Lee","year":"2015","unstructured":"Lee JJ, Loh K, Yap Y-S (2015) PI3K\/Akt\/mTOR inhibitors in breast cancer. Cancer Biol Med 12:342\u2013354","journal-title":"Cancer Biol Med"},{"key":"5082_CR61","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1634\/theoncologist.2010-0402","volume":"16","author":"LF Hernandez-Aya","year":"2011","unstructured":"Hernandez-Aya LF, Gonzalez-Angulo AM (2011) Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist 16:404\u2013414","journal-title":"Oncologist"},{"key":"5082_CR62","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","unstructured":"Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61\u201370","journal-title":"Nature"},{"key":"5082_CR63","doi-asserted-by":"crossref","unstructured":"Gamrani S, Boukansa S, Benbrahim Z et al (2022) The Prognosis and Predictive Value of Estrogen Negative\/Progesterone Positive (ER-\/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute. Breast J; 2022: 9238804","DOI":"10.1155\/2022\/9238804"},{"key":"5082_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-025-07606-x","volume":"8","author":"A Ghosh","year":"2025","unstructured":"Ghosh A, Chaubal R, Das C et al (2025) Genomic hallmarks of endocrine therapy resistance in ER\/PR\u2009+\u2009HER2- breast tumours. Commun Biol 8:1\u201312","journal-title":"Commun Biol"},{"key":"5082_CR65","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/1758834017693195","volume":"9","author":"P Augereau","year":"2017","unstructured":"Augereau P, Patsouris A, Bourbouloux E et al (2017) Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy. Ther Adv Med Oncol 9:335\u2013346","journal-title":"Ther Adv Med Oncol"},{"key":"5082_CR66","doi-asserted-by":"publisher","first-page":"101738","DOI":"10.1016\/j.tranon.2023.101738","volume":"37","author":"H Chen","year":"2023","unstructured":"Chen H, Hu X, Wang D et al (2023) Association of PIK3CA mutation with outcomes in HER2-positive breast cancer treated with anti-HER2 therapy: A meta-analysis and bioinformatic analysis of TCGA\u2013BRCA data. Transl Oncol 37:101738","journal-title":"Transl Oncol"},{"key":"5082_CR67","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.4161\/cc.3.10.1164","volume":"3","author":"Y Samuels","year":"2004","unstructured":"Samuels Y, Velculescu VE (2004) Oncogenic mutations of PIK3CA in human cancers. Cell Cycle Georget Tex 3:1221\u20131224","journal-title":"Cell Cycle Georget Tex"},{"key":"5082_CR68","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.molmed.2018.08.003","volume":"24","author":"RR Madsen","year":"2018","unstructured":"Madsen RR, Vanhaesebroeck B, Semple RK (2018) Cancer-Associated PIK3CA mutations in overgrowth disorders. Trends Mol Med 24:856\u2013870","journal-title":"Trends Mol Med"},{"key":"5082_CR69","doi-asserted-by":"publisher","first-page":"R28","DOI":"10.1186\/bcr3113","volume":"14","author":"M Cizkova","year":"2012","unstructured":"Cizkova M, Susini A, Vacher S et al (2012) PIK3CA mutation impact on survival in breast cancer patients and in ER\u03b1, PR and ERBB2-based subgroups. Breast Cancer Res BCR 14:R28","journal-title":"Breast Cancer Res BCR"},{"key":"5082_CR70","first-page":"6055","volume":"11","author":"D Huang","year":"2019","unstructured":"Huang D, Tang L, Yang F et al (2019) PIK3CA mutations contribute to fulvestrant resistance in ER-positive breast cancer. Am J Transl Res 11:6055\u20136065","journal-title":"Am J Transl Res"},{"key":"5082_CR71","doi-asserted-by":"publisher","first-page":"628690","DOI":"10.3389\/fphar.2021.628690","volume":"12","author":"C Dong","year":"2021","unstructured":"Dong C, Wu J, Chen Y et al (2021) Activation of PI3K\/AKT\/mTOR pathway causes drug resistance in breast Cancer. Front Pharmacol 12:628690","journal-title":"Front Pharmacol"},{"key":"5082_CR72","first-page":"1249","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A, Alpelisib (2019) First Global Approval Drugs 79:1249\u20131253","journal-title":"First Global Approval Drugs"},{"key":"5082_CR73","doi-asserted-by":"publisher","first-page":"563e1","DOI":"10.1016\/j.clgc.2021.07.014","volume":"19","author":"J Cham","year":"2021","unstructured":"Cham J, Venkateswaran AR, Bhangoo M (2021) Targeting the PI3K-AKT-mTOR pathway in castration resistant prostate cancer: A review Article. Clin Genitourin Cancer 19:563e1\u201356563.e7","journal-title":"Clin Genitourin Cancer"},{"key":"5082_CR74","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s12079-022-00702-1","volume":"17","author":"M Hashemi","year":"2023","unstructured":"Hashemi M, Taheriazam A, Daneii P et al (2023) Targeting PI3K\/Akt signaling in prostate cancer therapy. J Cell Commun Signal 17:423\u2013443","journal-title":"J Cell Commun Signal"},{"key":"5082_CR75","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.3390\/ijms24032046","volume":"24","author":"E Tortorella","year":"2023","unstructured":"Tortorella E, Giantulli S, Sciarra A et al (2023) AR and PI3K\/AKT in prostate cancer: A Tale of two interconnected pathways. Int J Mol Sci 24:2046","journal-title":"Int J Mol Sci"},{"key":"5082_CR76","doi-asserted-by":"publisher","first-page":"378","DOI":"10.4103\/1008-682X.122876","volume":"16","author":"MP Edlind","year":"2014","unstructured":"Edlind MP, Hsieh AC (2014) PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl 16:378\u2013386","journal-title":"Asian J Androl"},{"key":"5082_CR77","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1535-6108(03)00215-0","volume":"4","author":"S Wang","year":"2003","unstructured":"Wang S, Gao J, Lei Q et al (2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4:209\u2013221","journal-title":"Cancer Cell"},{"key":"5082_CR78","doi-asserted-by":"publisher","first-page":"17082","DOI":"10.1038\/s41598-020-74086-w","volume":"10","author":"I Keraite","year":"2020","unstructured":"Keraite I, Alvarez-Garcia V, Garcia-Murillas I et al (2020) PIK3CA mutation enrichment and quantitation from blood and tissue. Sci Rep 10:17082","journal-title":"Sci Rep"},{"key":"5082_CR79","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1200\/JCO.21.02371","volume":"41","author":"PK Brastianos","year":"2023","unstructured":"Brastianos PK, Twohy EL, Gerstner ER et al (2023) Alliance A071401: phase II trial of focal adhesion kinase Inhibition in meningiomas with somatic NF2 mutations. J Clin Oncol Off J Am Soc Clin Oncol 41:618\u2013628","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"5082_CR80","unstructured":"Alliance for Clinical Trials in Oncology. Phase II Trial of SMO\/ AKT\/ NF2\/CDK Inhibitors in Progressive Meningiomas With SMO\/ AKT\/ NF2\/CDK Pathway Mutations. Clinical Trial Registration NCT02523014, clinicaltrials.gov, https:\/\/clinicaltrials.gov\/study\/NCT02523014(28 March 2025, accessed 3 May 2025)."}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05082-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05082-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05082-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T13:02:52Z","timestamp":1751288572000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05082-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["5082"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05082-1","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Michael Lim (Funding from Arbor Pharmaceuticals, Accuray, BMS, Novartis; Consultant: BMS, Merck, SQZ Biotechnologies, Tocagen, VBI; Patents: Combining Focused Radiation and Immunotherapy, Combining Local Chemotherapy and Immunotherapy; Shareholder: Egret Therapeutics). Michael Lim is also a member of the editorial board for the current Journal (JNO). All other authors have no conflict to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}